Clinical Trials Logo

Geographic Atrophy clinical trials

View clinical trials related to Geographic Atrophy.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06164587 Recruiting - Clinical trials for Age-Related Macular Degeneration

Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy

K8 for GA
Start date: April 18, 2024
Phase: Phase 1
Study type: Interventional

This interventional study is a single-center, open label, 26-week study, designed to evaluate the safety and treatment efficacy of K8 in patients with geographic atrophy (GA) due to age-related macular degeneration (AMD). Up to 5 subjects will receive study medication. Study treatment will be administered by intravitreal injections. Participants will have 7 scheduled visits - Screening with baseline (injection), safety visit 2 days after injection, week 4, week 13 (injection), safety visit 2 days after injection, week 17, week 26. Exams will look for continuous changes in visual acuity, change in area of geographic atrophy lesions in diagnostic imaging, response measured by multifocal electroretinogram, change in reading speed, and change in microperimetry response.

NCT ID: NCT06161584 Recruiting - Geographic Atrophy Clinical Trials

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Start date: September 28, 2023
Phase:
Study type: Observational

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT ID: NCT06018558 Recruiting - Geographic Atrophy Clinical Trials

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

ArMaDa
Start date: August 23, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD). This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 63 subjects.

NCT ID: NCT05961332 Recruiting - Geographic Atrophy Clinical Trials

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy

COCO-GA
Start date: October 6, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare measurements of geographic atrophy (GA) area between several types of imaging, in order to assess accuracy. The main question to answer is which imaging device provides measurements that are most similar to the standard of care device. Participants will be patients of a retina doctor at University Station Eye Clinic with geographic atrophy, and can expect to be in the study for 60-75 minutes.

NCT ID: NCT05949593 Recruiting - Geographic Atrophy Clinical Trials

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

PHOENIX
Start date: July 27, 2023
Phase: Phase 3
Study type: Interventional

This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.

NCT ID: NCT05893537 Recruiting - Clinical trials for Age-Related Macular Degeneration

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Start date: June 16, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.

NCT ID: NCT05839041 Recruiting - Clinical trials for Macular Degeneration

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

SIGLEC
Start date: May 2, 2023
Phase: Phase 2
Study type: Interventional

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.

NCT ID: NCT05811351 Recruiting - Geographic Atrophy Clinical Trials

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Start date: March 6, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

NCT ID: NCT05797896 Recruiting - Clinical trials for Macular Degeneration

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

i-GAIN
Start date: February 7, 2023
Phase:
Study type: Observational

An observational study to investigate the natural history and evaluate biomarkers of participants with geographic atrophy secondary to age-related macular degeneration

NCT ID: NCT05626114 Recruiting - Geographic Atrophy Clinical Trials

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Start date: March 24, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated.